## Abstract **BACKGROUND:** D,L‐__threo__‐Methylphenidate (D,L‐MPH) is marketed currently for attention deficit hyperactivity disorder in children. D‐__threo__‐methylphenidate (dexmethylphenidate; D‐MPH) is a refined formulation of D,L‐methylphenidate containing only the active enantiomer and was r
Developmental toxicity assessment of d,l-Methylphenidate and d-Methylphenidate in rats and rabbits
✍ Scribed by David A. Beckman; Marilynn Schneider; Maureen Youreneff; Francis L.S. Tse
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 181 KB
- Volume
- 83
- Category
- Article
- ISSN
- 1542-9733
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
## Abstract **BACKGROUND:** The oral administration of d,l‐methylphenidate (MPH) was designed to encompass the major part of postnatal development in the rat and to evaluate potential chronic effects. **METHODS:** Wistar Hannover rats were cross‐fostered on postpartum day 0 (day of birth) and were
Ritalin or methylphenidate (MPH) is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The present report describes the determination of plasma concentrations of D-threo- and L-threo-enantiomers of MPH in toxicokinetic (TK) studies in pregnant Wistar Hann
D-002 is a mixture of higher aliphatic alcohols, primarily isolated and purified from beeswax, that has moderate anti-inflammatory and effective anti-ulcer activity. In the present study the developmental toxicity in Sprague-Dawley rats and New Zealand White rabbits was evaluated. Doses of 100, 320
Embryo-fetal development studies with toxicokinetic evaluations were conducted in rats and rabbits after oral or intravenous administration of two endothelin receptor antagonists. In the rat studies, females were administered SB-217242 (0.01-300 mg/kg/day) orally or SB-209670 (0.01-50 mg/kg/day) int